Mestinon

Pyridostigmine bromide, the active ingredient in Mestinon, is an acetylcholinesterase inhibitor presented as an oral formulation for oral use. It is employed to improve neuromuscular transmission in patients with myasthenia gravis and to aid recovery of bowel motility after surgery. By reversibly inhibiting acetylcholinesterase, it raises acetylcholine levels at the neuromuscular junction, enhancing muscle contraction.

GNH USA supplies Mestinon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with distribution networks across Europe, Asia and the Americas.

Mestinon (pyridostigmine bromide) is indicated for conditions that involve reduced acetylcholine activity at the neuromuscular junction, primarily autoimmune and postoperative disorders.

Myasthenia gravis: improves muscle strength by enhancing neuromuscular transmission. Postoperative ileus: facilitates the return of normal bowel motility after abdominal surgery. Ocular myasthenia gravis: helps reduce eye muscle weakness and ptosis.

Adverse reactions to Mestinon may vary in frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Abdominal cramps - Increased salivation - Muscle cramps - Sweating

Serious or Rare Side Effects: - Cholinergic crisis (muscle weakness, respiratory failure) - Severe bronchospasm - Bradycardia or arrhythmias - Seizures - Anaphylactic reaction

When prescribing Mestinon, clinicians should consider several precautionary measures to minimize risk.

Dose adjustment in renal impairment: reduce dose based on renal function. Monitor for cholinergic excess: watch for signs such as muscle twitching, sweating, diarrhea. Caution in patients with asthma or COPD: may exacerbate bronchospasm. Avoid concurrent use with other anticholinesterases: increased risk of toxicity. Pregnancy and lactation: use only if benefit outweighs risk and under medical supervision. Store at room temperature: keep in the original container, protect from moisture.

Mestinon can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Neostigmine: additive cholinergic effects may cause crisis. - Beta‑blockers: may mask tachycardia signs of cholinergic excess. - Magnesium sulfate: potentiates neuromuscular blockade, increasing risk of respiratory depression.

Moderate Interactions (Monitor Closely): - Aminoglycoside antibiotics (e.g., gentamicin): may reduce pyridostigmine effectiveness. - Loop diuretics (e.g., furosemide): can increase pyridostigmine plasma levels. - Succinylcholine (anesthetic): may enhance neuromuscular effects, requiring dose adjustment.